Fig. 6: The anti-GBM effect of combined TMZ and anti-CD47 antibody treatment is augmented by adjuvant PD-1 blockade. | Nature Communications

Fig. 6: The anti-GBM effect of combined TMZ and anti-CD47 antibody treatment is augmented by adjuvant PD-1 blockade.

From: Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity

Fig. 6

a Combination TMZ and anti-CD47 antibody treatment significantly elevated the level of IFNγ within tumors. Scale bar = 200 μm, Combo, n = 4; other groups, n = 5. **p < 0.01, one-side ANOVA with Bonferroni post hoc correction. b PD-1 (good responders, n = 7; poor responders, n = 4) and PD-L1 (good responders, n = 6; poor responders, n = 4) expression levels were notably elevated in GBM treated with combination TMZ and anti-CD47 antibody treatment. **p < 0.01, unpaired Student’s t test. c The addition of an adjuvant anti-PD1 antibody treatment prolonged animal survival in mouse with GBM. Control and aPD-1, n = 10; aCD47 + TMZ, n = 8; aCD47 + TMZ + aPD1, n = 9. **p < 0.01, log-rank test. d Proposed schematic of bridging the innate and adaptive immune responses by phagocytosis induction. Calr calreticulin. TCR T-cell receptor. All error bars = mean ± standard deviation.

Back to article page